About
Arthur Machlenkin, PhD, is an Israeli biotech executive and scientist. As of May 2024, Pluri identified him as its Chief Scientific Officer in the company's investor presentation. Earlier published immunology research also places him among the scientific contributors at the Weizmann Institute of Science on tumor-immunology work.
Areas of interest
biotechcell therapyimmunologyregenerative medicineoncology